Emergent BioSolutions announced that the FDA has approved CYFENDUS, or Anthrax Vaccine Adsorbed, Adjuvanted, previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. The efficacy of CYFENDUS vaccine for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax. CYFENDUS vaccine is comprised of Anthrax Vaccine Adsorbed, or AVA, and an additional adjuvant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EBS:
- Emergent Bio (NYSE:EBS) Soars on Approval for Anthrax Vaccine
- Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
- Emergent BioSolutions falls -6.3%
- Emergent BioSolutions Announces CEO Transition
- Emergent BioSolutions CEO Robert Kramer to retire, Haywood Miller named interim